Ovarian Cancer

ClinicalJuly 11, 2026

GSK's Mo-Rez Evaluated in 1L Maintenance for HRd Ovarian Cancer in BEHOLD-Ovarian03 Trial

The BEHOLD-Ovarian03 trial is assessing the efficacy and safety of mocertatug rezetecan (Mo-Rez) in combination with bevacizumab versus bevacizumab alone in first-line maintenance treatment of HRd ovarian cancer.

Companies

Assets

Recent signals(10)

Iparomlimab and Tovorilimab Combined with Bevacizumab in Advanced Ovarian Cancer Trial

NCI Study on High-Risk Breast/Ovarian Cancer Families to Enhance Genetic Understanding

GSK's Mo-Rez Evaluated in 1L Maintenance for HRd Ovarian Cancer in BEHOLD-Ovarian03 Trial

Phase 2 Trial of Chemoimmunotherapy with DC Vaccines for Recurrent Ovarian Cancer

Discovery of EGFR L858R-targeting peptide shows promise against ovarian cancer

Merck's Sac-TMT Trial for Advanced Ovarian Cancer Aims to Improve Maintenance Treatment Outcomes

Targeted PEGylated PLGA Nanoparticles Enhance Hesperidin Delivery in Ovarian Cancer

Phase II Trial of M6620 and Gemcitabine in Recurrent Ovarian Cancer

CRLX101 and Paclitaxel Combination Study in Ovarian Cancer Initiated by NewLink Genetics

Polyploid Giant Cancer Cells Drive Aggressiveness in Ovarian Cancer and Indicate Poor Prognosis

Upcoming catalysts

Indications

Get signals before the market moves